Previous 10 | Next 10 |
home / stock / atbpf / atbpf news
- Data in November will inform Phase II trial expected to launch next quarter Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announ...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic (ȁ...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier tod...
2023-08-14 14:10:41 ET More on Antibe Therapeutics Antibe Therapeutics teams up with Dalriada Drug Discovery to accelerate pipeline expansion Seeking Alpha’s Quant Rating on Antibe Therapeutics Earnings data for Antibe Therapeutics For further details see:...
- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study - PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 - Ended quarter with $34.3 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: AT...
2023-06-29 16:08:54 ET Antibe Therapeutics press release ( OTCQX:ATBPF ): FY GAAP EPS of -$0.37. Cash Position: As of March 31, 2023, the Company had available cash balance and term deposits totaling $38.9 million, compared to $54.8 million as at March 31, 2022. Gene...
- Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway - PK/PD study results expected in calendar Q4 2023 with Phase II initiation in Q1 2024 - Ended year with $38.9 million in cash and equivalents Antibe Therapeutics Inc. (TSX: ATE, OTCQX: A...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the Precision in Clinical Trials Summit being held in Boston on May 1 ȁ...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference being held in...
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update. CRO Selected for PK/PD Study for Otenaproxesul’s New Formu...
News, Short Squeeze, Breakout and More Instantly...
Biomerieux (BMXMF) is expected to report for Q1 2024 Conn's Inc. (CONN) is expected to report $-0.65 for Q1 2025 Cognetivity Neurosciences Ltd (CGNSF) is expected to report for quarter end 2024-04-30 Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q1 2024 China Jo-Jo ...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the " CCAA "), has been granted by the Ontario Sup...
Antibe Therapeutics Inc. (“ Antibe ” or the “ Company ”) (TSX: ATE, OTCQX: ATBPF) announced that it intends to file an application today with the Ontario Superior Court of Justice (Commercial List) (the " Court ") for an Initial Order under the Companies'...